IRONWOOD PHARMACEUTICALS, INC. Impairment of Intangible Assets, Finite-lived
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Impairment of Intangible Assets, Finite-lived of $151.79 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2021-02-17
- IRONWOOD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2018-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2018-09-30 was $151.79M.
- IRONWOOD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2018-06-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2018-03-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2018 was $151.79M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $151.79M derived: sum of 2 quarters · filed 2021-02-17 | $151.79M derived: sum of 3 quarters · filed 2021-02-17 | $151.79M 10-K · filed 2021-02-17 |
| 2018-09-30 | $151.79M 10-Q · filed 2019-10-31 | $151.79M derived: sum of 2 quarters · filed 2019-10-31 | $151.79M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $0.00 10-Q · filed 2018-08-06 | ||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-04 | |||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |